Denosumab dosing schedule for osteoporosis treatment?

• A. Subcutaneous injection every six months
• B. Oral tablet daily
• C. Intravenous infusion monthly
• D. Subcutaneous injection weekly

Answer: (A)

Denosumab provides a sustained antiresorptive effect by inhibiting RANKL, which lowers osteoclast formation and bone resorption. To maintain this effect, it is given as a subcutaneous injection every six months (typically 60 mg per dose). This biannual schedule aligns with its pharmacokinetics and the need for ongoing suppression of bone turnover without daily or monthly dosing.

The other options don’t fit because denosumab is not taken as an oral daily tablet, not given by intravenous infusion on a monthly schedule, and not administered as a weekly subcutaneous injection. It’s also important to note that stopping denosumab can lead to a rapid rebound increase in bone turnover and fracture risk, so planning a transition to another antiresorptive if therapy is interrupted is essential, along with calcium and vitamin D supplementation.